Live Chat
Today's Hours: 8:00am - 8:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Article
    Chao TF, Lu TM, Lin YJ, Tsao HM, Chang SL, Lo LW, Hu YF, Tuan TC, Hsieh MH, Chen SA.
    PLoS One. 2013;8(8):e71675.
    OBJECTIVES: Elevated plasma levels of asymmetric dimethylarginine (ADMA) have been reported to be associated with endothelial dysfunction, inflammation, and oxidative stress in multiple cardiovascular diseases. This study aimed to investigate whether ADMA was a predictor of clinical outcomes in atrial fibrillation (AF).
    METHODS AND RESULTS: From 2006-2009, 990 individuals were referred to our institution for coronary angiography. Among these patients, 141 subjects with a diagnosis of AF, including 52 paroxysmal AF (PAF) and 89 non-paroxysmal AF (non-PAF) patients, were identified as the study population. Plasma ADMA levels were measured. An adverse event was defined as the occurrence of ischemic stroke or cardiovascular death. The ADMA levels were higher in AF than non-AF patients (0.50 ± 0.13 versus 0.45 ± 0.07 µmol/L; p<0.001). Besides, non-PAF patients had higher ADMA levels than PAF patients (0.52 ± 0.15 versus 0.48 ± 0.08 µmol/L; p<0.001). During the follow-up of 30.7±14.4 months, 21 patients (14.9%) experienced adverse events, including cardiovascular death in 7 patients and ischemic stroke in 14. ADMA level, CHA2DS2-VASc score, and left atrial diameter were independent predictors of adverse events in the multivariate analysis. At a cutoff-value of 0.55 µmol/L, the Kaplan-Meier survival analysis showed that patients with a high ADMA level had a higher event rate during the follow-up period.
    CONCLUSIONS: A higher level of ADMA was a risk factor of adverse events in AF patients, which was independent from the CHA2DS2-VASc score. It deserves to further study whether ADMA could potentially refine the clinical risk stratification in AF.
    Digital Access Access Options
  • Article
    Wu H, Zhang Y, Wei J, Bovet P, Zhao M, Liu W, Xi B.
    Environ Sci Pollut Res Int. 2022 Oct;29(47):71665-71675.
    This study aims to examine the association between short-term exposure to ambient PM1, PM1-2.5, and PM2.5 and forced vital capacity (FVC). Population data were obtained from a school-based cross-sectional survey in Shandong in 2014. Distributed lag non-linear models were used to examine the association between exposure to PM1, PM1-2.5, and PM2.5 and FVC at the day of FVC measurement and the previous 6 days (lag 0 to 6 days). A total of 35,334 students aged 9 to 18 years were included in the study, and the mean exposure concentrations of ambient PM1, PM1-2.5, and PM2.5 for them were 47.4 (standard deviation [SD] = 21.3) μg/m3, 32.8 (SD = 32.2) μg/m3, and 80.1 (SD = 47.7) μg/m3, respectively. An inter-quartile range (IQR, 24 μg/m3) increment in exposure to PM1 was significantly associated with a lower FVC at lag 0 and lag 1 day (β =  - 80 mL, 95% CI =  - 119, - 42, and β =  - 37 mL, 95% CI =  - 59, - 16, respectively), and an IQR (54 μg/m3) increment in exposure to PM2.5 was significantly associated with a lower FVC at lag 0 and lag 1 day (β =  - 57 mL, 95% CI =  - 89, - 18, and β =  - 34 mL, 95% CI =  - 56, - 12, respectively) after adjustment for gender, age, body mass index category, residence, month of the survey, intake of eggs, intake of milk, physical activity, and screen time. No significant associations were observed for PM1-2.5. The inverse associations of PM1 and PM2.5 with FVC were larger in males, younger children, those overweight or obese, and those with insufficient physical activity levels. Short-term exposure to ambient PM1 and PM2.5 was associated with decreased FVC, and PM1 may be the primary fraction of PM2.5 causing the adverse pulmonary effects. Our findings emphasize the need to address ambient PM, especially PM1, pollution for affecting pulmonary health in children and adolescents.
    Digital Access Access Options
  • Article
    Hanna F, Wu P, Heald A, Fryer A.
    BMJ. 2023 07 04;382:e071675.
    Gestational diabetes mellitus (GDM) and polycystic ovarian syndrome (PCOS) represent two of the highest risk factors for development of type 2 diabetes mellitus in young women. As these increasingly common conditions generally affect younger women, early detection of dysglycemia is key if preventative measures are to be effective. While international guidance recommends screening for type 2 diabetes, current screening strategies suffer from significant challenges.First, guidance lacks consensus in defining which tests to use and frequency of monitoring, thereby sending mixed messages to healthcare professionals.Second, conformity to guidance is poor, with only a minority of women having tests at the recommended frequency (where specified). Approaches to improve conformity have focused on healthcare related factors (largely technology driven reminder systems), but patient factors such as convenience and clear messaging around risk have been neglected.Third, and most critically, current screening strategies are too generic and rely on tests that become abnormal far too late in the trajectory towards dysglycemia to offer opportunities for effective preventative measures. Risk factors show wide interindividual variation, and insulin sensitivity and β cell function are often abnormal during pre-diabetes stage, well before frank diabetes.New, consistent, targeted screening strategies are required that incorporate early, prevention focused testing and personalised risk stratification.
    Digital Access Access Options
  • Book
    Marilyn H. Oermann.
    Summary: "Writing for publication in nursing is essential to disseminate evidence, share initiatives and innovations with others, provide new information to keep nurses up to date, and communicate the findings of research. Writing manuscripts is hard work, but the process can be simplified by understanding how to develop a manuscript and submit it for publication. Writing for Publication in Nursing, now in its fifth edition, was prepared for beginning and experienced authors, for nurses, and for graduate students in nursing to guide them in writing literature reviews, research reports, evidence syntheses, quality improvement and clinical articles, and other types of papers"-- Provided by publisher.

    Contents:
    Part I: Preparing to Write
    Getting Started
    Selecting a Journal
    Authorship and Preparing to Write
    Reviewing the Literature
    Part II: Writing Research, Evidence Synthesis, Clinical Practice, and Quality Improvement Articles
    Research Reports
    Evidence Syntheses : Conducting and Reporting Reviews
    Clinical Practice Articles
    Articles Reporting Quality Improvement
    Part III: Chapters, Books, and Other Forms of Writing
    Other Types of Writing
    Books and Book Chapters
    Part IV: The Writing Process
    Writing Process
    References
    Tables and Figures
    Part V: Final Paper Through Publication
    Final Paper and Submission to Journal
    Editorial Review Process
    Publishing Process
    Open Access Journals.
    Digital Access R2Library [2024]